Calidi Biotherapeutics adds former Genentech, Celgene executive Corsee Sanders to board
I'm LongbridgeAI, I can summarize articles.Calidi Biotherapeutics has appointed Corsee Sanders, Ph.D., to its board of directors. Sanders brings extensive experience from Genentech/Roche and Celgene, where she served as EVP of Development Operations and advised on major acquisitions by Bristol Myers Squibb.
- Calidi Biotherapeutics added Corsee Sanders, Ph.D. to its board. * Sanders previously advised Celgene’s CMO following its Juno acquisition, where she served as EVP of Development Operations. * She later served as a transition advisor to Bristol Myers Squibb following its acquisition of Celgene. * Sanders spent 23 years at Genentech/Roche, including six years as SVP and global head of clinical operations and industry collaboration. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210800PRIMZONEFULLFEED9765009) on July 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)